Abstract
Purpose: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p- CLL. Patients and Methods: Baseline data from patients, for whom information on the presence of 17p- CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. Results: A total of 44 patients with 17p- CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p- CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53% of patients were in remission. Reduced-intensity conditioning was applied in 89% of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43% of patients, and extensive chronic GVHD occurred in 53% of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44% and 37%, respectively. The cumulative incidence of progressive disease at 4 years was 34%. No late relapse occurred in nine patients with a follow-up longer than 4 years. Conclusion: Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p- CLL.
| Original language | English |
|---|---|
| Pages (from-to) | 5094-5100 |
| Number of pages | 7 |
| Journal | Journal of Clinical Oncology |
| Volume | 26 |
| Issue number | 31 |
| DOIs | |
| Publication status | Published - Nov 1 2008 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion : A retrospective European group for blood and marrow transplantation analysis. / Schetelig, Johannes; Van Biezen, Anja; Brand, Ronald; Caballero, Dolores; Martino, Rodrigo; Itala, Maija; García-Marco, José A.; Volin, Liisa; Schmitz, Norbert; Schwerdtfeger, Rainer; Ganser, Arnold; Onida, Francesco; Mohr, Brigitte; Stilgenbauer, Stephan; Bornhäuser, Martin; De Witte, Theo; Dreger, Peter.
In: Journal of Clinical Oncology, Vol. 26, No. 31, 01.11.2008, p. 5094-5100.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion
T2 - A retrospective European group for blood and marrow transplantation analysis
AU - Schetelig, Johannes
AU - Van Biezen, Anja
AU - Brand, Ronald
AU - Caballero, Dolores
AU - Martino, Rodrigo
AU - Itala, Maija
AU - García-Marco, José A.
AU - Volin, Liisa
AU - Schmitz, Norbert
AU - Schwerdtfeger, Rainer
AU - Ganser, Arnold
AU - Onida, Francesco
AU - Mohr, Brigitte
AU - Stilgenbauer, Stephan
AU - Bornhäuser, Martin
AU - De Witte, Theo
AU - Dreger, Peter
PY - 2008/11/1
Y1 - 2008/11/1
N2 - Purpose: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p- CLL. Patients and Methods: Baseline data from patients, for whom information on the presence of 17p- CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. Results: A total of 44 patients with 17p- CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p- CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53% of patients were in remission. Reduced-intensity conditioning was applied in 89% of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43% of patients, and extensive chronic GVHD occurred in 53% of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44% and 37%, respectively. The cumulative incidence of progressive disease at 4 years was 34%. No late relapse occurred in nine patients with a follow-up longer than 4 years. Conclusion: Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p- CLL.
AB - Purpose: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p- CLL. Patients and Methods: Baseline data from patients, for whom information on the presence of 17p- CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. Results: A total of 44 patients with 17p- CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p- CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53% of patients were in remission. Reduced-intensity conditioning was applied in 89% of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43% of patients, and extensive chronic GVHD occurred in 53% of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44% and 37%, respectively. The cumulative incidence of progressive disease at 4 years was 34%. No late relapse occurred in nine patients with a follow-up longer than 4 years. Conclusion: Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p- CLL.
UR - http://www.scopus.com/inward/record.url?scp=55549097826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55549097826&partnerID=8YFLogxK
U2 - 10.1200/JCO.2008.16.2982
DO - 10.1200/JCO.2008.16.2982
M3 - Article
VL - 26
SP - 5094
EP - 5100
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 31
ER -